With No­var­tis and Google jump­ing in, Medicxi un­veils a $300M late-stage biotech fund with a transat­lantic scope

The Eu­ro­pean ven­ture group Medicxi is stak­ing out some new ter­rain in biotech in­vest­ing. And they’re bring­ing in two big play­ers — No­var­tis and Google’s Ver­i­ly — as key back­ers.

Known for a long­time strat­e­gy that clear­ly and care­ful­ly con­cen­trates their at­ten­tion on sin­gle-as­set or­ga­ni­za­tions that start out ear­ly on a lim­it­ed bud­get, Medicxi has added a new, $300 mil­lion fund that will fo­cus on late-stage biotech in­vest­ments. But they still want to fall in love with a top drug be­fore they buy in.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.